Advertisement

Index by author

September 01, 2014; Volume 350,Issue 3

  1. Kaiser, M.

    1. Tanshinone II A Sulfonate, but Not Tanshinone II A, Acts as Potent Negative Allosteric Modulator of the Human Purinergic Receptor P2X7
      M. Kaiser, H. Sobottka, W. Fischer, M. Schaefer and W. Nörenberg
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 531-542; DOI: https://doi.org/10.1124/jpet.114.214569

  2. Kalinichev, Mikhail

    1. Characterization of the Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 ADX88178 in Rodent Models of Neuropsychiatric Disorders
      Mikhail Kalinichev, Emmanuel Le Poul, Christelle Boléa, Françoise Girard, Brice Campo, Massimiliano Fonsi, Isabelle Royer-Urios, Susan E. Browne, Jason M. Uslaner, Matthew J. Davis, Jacob Raber, Robert Duvoisin, Simon T. Bate, Ian J. Reynolds, Sonia Poli and Sylvain Celanire
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 495-505; DOI: https://doi.org/10.1124/jpet.114.214437

  3. Kang, Jihee Lee

    1. RhoA/Phosphatidylinositol 3-Kinase/Protein Kinase B/Mitogen-Activated Protein Kinase Signaling after Growth Arrest–Specific Protein 6/Mer Receptor Tyrosine Kinase Engagement Promotes Epithelial Cell Growth and Wound Repair via Upregulation of Hepatocyte Growth Factor in Macrophages
      Ye-Ji Lee, Hyun-Jung Park, So-Youn Woo, Eun-Mi Park and Jihee Lee Kang
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 563-577; DOI: https://doi.org/10.1124/jpet.114.215673

  4. Kanie, Sayoko

    1. Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder
      Morihiro Fujimura, Naoki Izumimoto, Shinobu Momen, Satoru Yoshikawa, Ryosuke Kobayashi, Sayoko Kanie, Mikito Hirakata, Toshikazu Komagata, Satoshi Okanishi, Tadatoshi Hashimoto, Naoki Yoshimura and Koji Kawai
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 543-551; DOI: https://doi.org/10.1124/jpet.114.214031

  5. Katzehendler, Jehoshua

    1. Vimocin and Vidapin, Cyclic KTS Peptides, Are Dual Antagonists of α1β1/α2β1 Integrins with Antiangiogenic Activity
      Tatjana Momic, Jehoshua Katzehendler, Ofra Benny, Adi Lahiani, Gadi Cohen, Efrat Noy, Hanoch Senderowitz, Johannes A. Eble, Cezary Marcinkiewicz and Philip Lazarovici
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 506-519; DOI: https://doi.org/10.1124/jpet.114.214643

  6. Kawai, Koji

    1. Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder
      Morihiro Fujimura, Naoki Izumimoto, Shinobu Momen, Satoru Yoshikawa, Ryosuke Kobayashi, Sayoko Kanie, Mikito Hirakata, Toshikazu Komagata, Satoshi Okanishi, Tadatoshi Hashimoto, Naoki Yoshimura and Koji Kawai
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 543-551; DOI: https://doi.org/10.1124/jpet.114.214031

  7. Kikuchi, Tetsuro

    1. Brexpiprazole II: Antipsychotic-Like and Procognitive Effects of a Novel Serotonin-Dopamine Activity Modulator
      Kenji Maeda, Linda Lerdrup, Haruhiko Sugino, Hitomi Akazawa, Naoki Amada, Robert D. McQuade, Tine Bryan Stensbøl, Christoffer Bundgaard, Jørn Arnt and Tetsuro Kikuchi
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 605-614; DOI: https://doi.org/10.1124/jpet.114.213819
    2. Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator
      Kenji Maeda, Haruhiko Sugino, Hitomi Akazawa, Naoki Amada, Jun Shimada, Takashi Futamura, Hiroshi Yamashita, Nobuaki Ito, Robert D. McQuade, Arne Mørk, Alan L. Pehrson, Morten Hentzer, Vibeke Nielsen, Christoffer Bundgaard, Jørn Arnt, Tine Bryan Stensbøl and Tetsuro Kikuchi
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 589-604; DOI: https://doi.org/10.1124/jpet.114.213793

  8. Klaus, Christine R.

    1. DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells
      Christine R. Klaus, Dorothy Iwanowicz, Danielle Johnston, Carly A. Campbell, Jesse J. Smith, Mikel P. Moyer, Robert A. Copeland, Edward J. Olhava, Margaret Porter Scott, Roy M. Pollock, Scott R. Daigle and Alejandra Raimondi
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 646-656; DOI: https://doi.org/10.1124/jpet.114.214577

  9. Klein, Thomas

    1. The Sodium Glucose Cotransporter Type 2 Inhibitor Empagliflozin Preserves β-Cell Mass and Restores Glucose Homeostasis in the Male Zucker Diabetic Fatty Rat
      Henrik H. Hansen, Jacob Jelsing, Carl Frederik Hansen, Gitte Hansen, Niels Vrang, Michael Mark, Thomas Klein and Eric Mayoux
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 657-664; DOI: https://doi.org/10.1124/jpet.114.213454

  10. Kobayashi, Ryosuke

    1. Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder
      Morihiro Fujimura, Naoki Izumimoto, Shinobu Momen, Satoru Yoshikawa, Ryosuke Kobayashi, Sayoko Kanie, Mikito Hirakata, Toshikazu Komagata, Satoshi Okanishi, Tadatoshi Hashimoto, Naoki Yoshimura and Koji Kawai
      Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 543-551; DOI: https://doi.org/10.1124/jpet.114.214031
« Previous (Pages : 1 2 ... 2) Next »
Back to top

In this issue

Advertisement